AstraZeneca announced results from the PEGASUS-TIMI 54 study that evaluated Brilinta (ticagrelor) tablets with low-dose aspirin vs. placebo for the chronic secondary prevention of atherothrombotic events in patients with a history of heart attack 1–4 years prior to study enrollment. Study findings were presented during the American College of Cardiology's 64th Annual Scientific Session and Expo, and were published in the New England Journal of Medicine.
PEGASUS-TIMI 54 (PrEvention with TicaGrelor of SecondAry Thrombotic Events in High-RiSk Patients with Prior AcUte Coronary Syndrome - Thrombolysis In Myocardial Infarction Study Group) was a large outcomes trial that enrolled over 21,000 patients across over 1,100 sites. Key findings showed that bot...
Also read: Andy Murray withdraws from Miami Open